Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment
Executive Summary
Shares in UK company Indivior jumped by more than 12% on Aug. 17 on the LSE on the back of top-line Phase III data for its monthly buprenorphine depot for opioid addiction, and confirmation that a Q4 2017 US approval is still within its sights.
You may also be interested in...
Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market
US FDA approval of Sublocade, the company's once-monthly buprenorphine depot injection, may help Indivior defend its opioid addiction franchise from generics and the competing Alkermes product Vivitrol. But another new rival is expected soon – a once-monthly product from Braeburn.
Ten Approvals To Look Out For In Q4
From AstraZeneca’s benralizumab in asthma to Kite Pharma’s CAR-T therapy, Scrip takes a look at some of the more interesting drug approvals expected by the end of the year, with the help of analysts from Informa's Biomedtracker.
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
The latest drug development news and US FDA highlights from our Performance Tracker.